Loading...
Loading...
Every disease MedicOath is actively working on, from initial AI hypothesis through to open-source manufacturing. Real-time progress across the full discovery pipeline.
CRISPR-Cas9 BCL11A enhancer editing — confidence 88%
Prometheus has generated a novel therapeutic hypothesis
Under community validation via Evidence
Confirmed by peer consensus and safety review
Active fundraising via OpenFund
Laboratory testing and dose optimisation
Human trials via CureNet participants
Entered: Feb 26, 2026Open-source production protocol on IPFS
Free and available to all humanity — CC0
Antimicrobial prophylaxis with tissue regeneration factor — confidence 61%
Prometheus has generated a novel therapeutic hypothesis
Entered: Apr 9, 2026Under community validation via Evidence
Confirmed by peer consensus and safety review
Active fundraising via OpenFund
Laboratory testing and dose optimisation
Human trials via CureNet participants
Open-source production protocol on IPFS
Free and available to all humanity — CC0
Antimicrobial prophylaxis with tissue regeneration factor
Lamin A farnesyltransferase inhibitor optimisation
Mycolactone toxin neutralising antibody
Miltefosine + paromomycin combination protocol
Fexinidazole oral monotherapy optimisation
Benznidazole nano-formulation for chronic phase
Rituximab B-cell depletion for autoimmune ME subtype
COL7A1 gene replacement via AAV vector
Post-symptomatic antiviral cocktail
Rapamycin analogue for mTOR pathway modulation
TBK1 kinase inhibition for neuroinflammation reduction
CRISPR-Cas9 BCL11A enhancer editing
Temozolomide + oncolytic virus combination
CRISPR-Cas13 targeting LAT RNA in trigeminal ganglia
Stromal depletion + checkpoint inhibitor combination
Exon-skipping antisense oligonucleotide optimisation
Stem cell derived beta-cell encapsulation
TBK1-mediated tau clearance via AMPK pathway